John Boyce

Waltham, Massachusetts, United States
John is a genomics and diagnostics serial entrepreneur who specializes in building and positioning companies for either acquisition or IPO. He is an energetic business leader who has successfully raised over $500MM in funding from venture capital, strategics, as well as from private investors. John has extensive connections and inroads to the top leaders in pharma, biotech, and diagnostic companies, as well as venture capital and investment banking. John was recently President and CEO of Exosome Diagnostics, a liquid biopsy company that he turned around and drove to a successful acquisition for $575MM ($250MM upfront) to Bio-Techne within ~2.5 years, resulting in a ~6X return to investors. John came to the company in October 2015 when the company was critically low on cash and struggling to close its Series B round, with no external investors interested. Within ~3 months, John restructured and re-positioned the company by implementing a "3 Pillar Strategy", developed a Companion Diagnostics division and Regulatory division, and brought in Tiger Management as an investor, to close the B round for $60MM. Subsequently, John closed an oversubscribed Series C round for $33MM, and drove the company to its successful exit. In 2014 John was made a Fellow at Harvard University and teaches "Entrepreneurship and Innovation" (ES-139).
Speaking In
10:30 AM - 11:45 AM
Thursday, June 6
Head turning deals in precision medicine typically result in competitor companies analyzing every…